🎉 M&A multiples are live!
Check it out!

GuangYuYuan Chinese Valuation Multiples

Discover revenue and EBITDA valuation multiples for GuangYuYuan Chinese and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

GuangYuYuan Chinese Overview

About GuangYuYuan Chinese

GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more.


Founded

1996

HQ

China
Employees

3.1K+

Website

topsun.com

Financials

LTM Revenue $171M

LTM EBITDA $22.7M

EV

$1.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

GuangYuYuan Chinese Financials

As of September 2025, GuangYuYuan Chinese reported last 12-month revenue of $171M and EBITDA of $22.7M.

In the same period, GuangYuYuan Chinese generated $126M in LTM gross profit and $10.4M in net income.

See GuangYuYuan Chinese valuation multiples based on analyst estimates

GuangYuYuan Chinese P&L

In the most recent fiscal year, GuangYuYuan Chinese reported revenue of $171M and EBITDA of $19.8M.

GuangYuYuan Chinese expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See GuangYuYuan Chinese valuation multiples based on analyst estimates
LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $171M XXX $171M XXX XXX XXX
Gross Profit $126M XXX $126M XXX XXX XXX
Gross Margin 74% XXX 74% XXX XXX XXX
EBITDA $22.7M XXX $19.8M XXX XXX XXX
EBITDA Margin 13% XXX 12% XXX XXX XXX
EBIT $12.8M XXX $26.0M XXX XXX XXX
EBIT Margin 7% XXX 15% XXX XXX XXX
Net Profit $10.4M XXX $10.4M XXX XXX XXX
Net Margin 6% XXX 6% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

GuangYuYuan Chinese Stock Performance

GuangYuYuan Chinese has current market cap of CNY 9.5B (or $1.3B), and EV of CNY 9.2B (or $1.3B).

Market Cap Evolution

GuangYuYuan Chinese Stock Data

As of October 17, 2025, GuangYuYuan Chinese's stock price is CNY 19 (or $3).

See GuangYuYuan Chinese trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.3B $1.3B XXX XXX XXX XXX $0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

GuangYuYuan Chinese Valuation Multiples

GuangYuYuan Chinese's trades at 7.5x EV/Revenue multiple, and 65.3x EV/EBITDA.

See valuation multiples for GuangYuYuan Chinese and 15K+ public comps

GuangYuYuan Chinese Financial Valuation Multiples

As of October 17, 2025, GuangYuYuan Chinese has market cap of $1.3B and EV of $1.3B.

Equity research analysts estimate GuangYuYuan Chinese's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

GuangYuYuan Chinese has a P/E ratio of 127.9x.

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $1.3B XXX $1.3B XXX XXX XXX
EV (current) $1.3B XXX $1.3B XXX XXX XXX
EV/Revenue 7.5x XXX 7.5x XXX XXX XXX
EV/EBITDA 56.7x XXX 65.3x XXX XXX XXX
EV/EBIT 101.0x XXX 49.5x XXX XXX XXX
EV/Gross Profit 10.2x XXX n/a XXX XXX XXX
P/E 127.9x XXX 127.1x XXX XXX XXX
EV/FCF n/a XXX 88.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get GuangYuYuan Chinese Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

GuangYuYuan Chinese Margins & Growth Rates

GuangYuYuan Chinese's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $32K for the same period.

GuangYuYuan Chinese's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

GuangYuYuan Chinese's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for GuangYuYuan Chinese and other 15K+ public comps

GuangYuYuan Chinese Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin 13% XXX 12% XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX $0.1M XXX XXX XXX
Opex per Employee XXX XXX $32K XXX XXX XXX
S&M Expenses to Revenue XXX XXX 38% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 3% XXX XXX XXX
Opex to Revenue XXX XXX 58% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

GuangYuYuan Chinese Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

GuangYuYuan Chinese M&A and Investment Activity

GuangYuYuan Chinese acquired  XXX companies to date.

Last acquisition by GuangYuYuan Chinese was  XXXXXXXX, XXXXX XXXXX XXXXXX . GuangYuYuan Chinese acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by GuangYuYuan Chinese

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About GuangYuYuan Chinese

When was GuangYuYuan Chinese founded? GuangYuYuan Chinese was founded in 1996.
Where is GuangYuYuan Chinese headquartered? GuangYuYuan Chinese is headquartered in China.
How many employees does GuangYuYuan Chinese have? As of today, GuangYuYuan Chinese has 3.1K+ employees.
Is GuangYuYuan Chinese publicy listed? Yes, GuangYuYuan Chinese is a public company listed on SHG.
What is the stock symbol of GuangYuYuan Chinese? GuangYuYuan Chinese trades under 600771 ticker.
When did GuangYuYuan Chinese go public? GuangYuYuan Chinese went public in 1996.
Who are competitors of GuangYuYuan Chinese? Similar companies to GuangYuYuan Chinese include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of GuangYuYuan Chinese? GuangYuYuan Chinese's current market cap is $1.3B
What is the current revenue of GuangYuYuan Chinese? GuangYuYuan Chinese's last 12 months revenue is $171M.
What is the current EV/Revenue multiple of GuangYuYuan Chinese? Current revenue multiple of GuangYuYuan Chinese is 7.5x.
Is GuangYuYuan Chinese profitable? Yes, GuangYuYuan Chinese is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of GuangYuYuan Chinese? GuangYuYuan Chinese's last 12 months EBITDA is $22.7M.
What is GuangYuYuan Chinese's EBITDA margin? GuangYuYuan Chinese's last 12 months EBITDA margin is 13%.
What is the current EV/EBITDA multiple of GuangYuYuan Chinese? Current EBITDA multiple of GuangYuYuan Chinese is 56.7x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.